COSTA MESA, Calif., May 2 /PRNewswire-FirstCall/ -- CNS Response, Inc. (OTC Bulletin Board: CNSO) announced today that Dr. Daniel Hoffman, M.D., Chief Medical Officer, CNS Response, Dr. Henry Harbin, M.D., Board Member, CNS Response and Dr. James Greenblatt, M.D., Chief Medical Officer, Walden Behavioral Care Inpatient Psychiatry and Eating Disorder Programs, will deliver a presentation on Referenced EEG-guided personalized medicine and its potential for treating patients with behavioral disorders at the National Council for Community Behavioral Healthcare 38th National Council Conference.
The presentation, titled "Personalized Medicine in Psychiatry: Using EEG-Guided Medication Decisions," will offer an overview of the science and current results of using Quantitative EEG's to predict psychotropic medication responses. Specific research from CNS Response's Referenced EEG (rEEG) and Aspect Medical's BRITE study will be reviewed, including the use of rEEG for treatment refractory Eating Disorder Patients.
rEEG uses traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify medication classes most likely to be needed and medications within those classes with the most probable treatment potential for each patient. The BRITE study predicts whether the SSRI's tested will alter certain EEG variables in order to predict a positive response within a few days of taking the medication. Implications for the future practice of psychiatry, including efficiency, cost savings, and effectiveness in treatment resistant populations, will be discussed.
The presentation, which is part of the Emerging Treatment Technologies track, will occur on Friday, May 2, 2008 from 3:45 p.m. to 5:15 p.m., EDT. The 38th National Council Conference is taking place in Boston, MA, at the Marriott Copley Place from May 1-3, 2008.
Further information on National Council for Community Behavioral Healthcare and the 38th National Council Conference can be found at http://www.thenationalcouncil.org.
About CNS Response
CNS Response is a life-sciences data company whose patented system provides treatment guidance to psychiatrists and other physicians for patients with behavioral (mental or addictive) disorders. This technology allows CNS Response to create and provide simple reports ("rEEG(R) Reports") that specifically guide physicians to treatment strategies based on the patient's own physiology.
rEEG(R) utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications within these classes with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70% or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.
In addition to providing analytical support to physicians, CNS Response is also an aid to pharmaceutical developers, who can use rEEG to (1) stratify study populations to improve the success of FDA clinical trials; (2) provide insight on effective therapeutic dosing of investigational drugs; (3) identify additional indications for psychiatric medications; (4) provide insight into effective drug combinations; and (5) discover opportunities for decision analytics and support. In addition to these applications, CNS Response continues to investigate the use of rEEG analysis for development of proprietary pharmaceutical opportunities.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters
discussed are forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995, as
amended. These statements involve risks and uncertainties as set forth in
the Company's filings with the Securities and Exchange Commission. These
risks and uncertainties could cause actual results to differ materially
from any forward-looking statements made herein.
Jason Rando / Jennifer Saunders
(646) 536-7033 / 7011
|SOURCE CNS Response, Inc.|
Copyright©2008 PR Newswire.
All rights reserved